Sex-Related Longitudinal Change of Motor, Non-Motor, and Biological Features in Early Parkinson's Disease.
Sex-Related Longitudinal Change of Motor, Non-Motor, and Biological Features in Early Parkinson's Disease.
复制标题
DOI：
10.3233/jpd-212892
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
Parkinson’s Progression Markers Initiative
中科院分区：
文献类型：
--
作者：
Picillo M;LaFontant DE;Bressman S;Caspell-Garcia C;Coffey C;Cho HR;Burghardt EL;Dahodwala N;Saunders-Pullman R;Tanner CM;Amara AW;Parkinson’s Progression Markers Initiative
对帕金森病 (PD) 中与性别相关的运动和非运动差异以及生物标志物的研究可能会改善精准医疗方法。检查早期帕金森病中运动和非运动特征以及生物标志物的性别相关纵向变化。我们比较了帕金森病进展标志物计划 (PPMI) 中未经治疗的帕金森病男性和女性（基线时 N = 423；65.5% 男性）的 5 年纵向变化，评估了疾病的运动和非运动表现； DaTscanTM 摄取的脑脊液 (CSF) 和多巴胺转运蛋白缺陷的生物测量。男性在自我报告的日常生活体验的运动（p< 0.001）和非运动（p = 0.009）方面经历了更大的纵向下降，因此男性的MDS-UPDRS第II部分每年增加1.27倍，而女性为0.7倍，而男性的MDS-UPDRS第I部分每年增加1.27倍。 0.98，而女性为 0.67。与女性相比，男性在 ON 药物状态下临床医生评估的运动特征有更多的纵向进展 (p = 0.010)，并且随着时间的推移需要更高的多巴胺能药物剂量 (p = 0.014)。达到特定疾病里程碑的时间以及脑脊液生物标志物和 DaTscanTM 摄取的纵向变化在性别上没有差异。男性自我评估的运动和非运动疾病负担较高，这可能是由于男性多巴胺能治疗反应不佳所致。然而，在关闭药物状态下使用基于临床医生的量表评估的疾病运动特征以及生物标志物并未显示出特定的性别相关进展模式。
Investigation of sex-related motor and non-motor differences and biological markers in Parkinson’s disease (PD) may improve precision medicine approach. To examine sex-related longitudinal changes in motor and non-motor features and biologic biomarkers in early PD. We compared 5-year longitudinal changes in de novo, untreated PD men and women (at baseline N = 423; 65.5%male) of the Parkinson’s Progression Markers Initiative (PPMI), assessing motor and non-motor manifestations of disease; and biologic measures in cerebrospinal fluid (CSF) and dopamine transporter deficit on DaTscanTM uptake. Men experienced greater longitudinal decline in self-reported motor (p < 0.001) and non-motor (p = 0.009) aspects of experiences of daily living, such that men had a yearly increase in MDS-UPDRS part II by a multiplicative factor of 1.27 compared to women at 0.7, while men had a yearly increase in MDS-UPDRS part I by a multiplicative factor of 0.98, compared to women at 0.67. Compared to women, men had more longitudinal progression in clinician-assessed motor features in the ON medication state (p = 0.010) and required higher dopaminergic medication dosages over time (p = 0.014). Time to reach specific disease milestones and longitudinal changes in CSF biomarkers and DaTscanTM uptake were not different by sex. Men showed higher self-assessed motor and non-motor burden of disease, with possible contributions from suboptimal dopaminergic therapeutic response in men. However, motor features of disease evaluated with clinician-based scales in the OFF medication state, as well as biological biomarkers do not show specific sex-related progression patterns.